PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1425020
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1425020
Emergency Contraceptive Pills (ECPS) Market size was valued at USD 1,045 Million in 2022, expanding at a CAGR of 2.5% from 2023 to 2030.
Emergency contraception refers to methods of contraception that can be used to prevent pregnancy after sexual intercourse. It is highly recommended to use these methods within 5 days, but their effectiveness is greater the sooner they are utilized after intercourse. Emergency contraceptive pills work by either preventing or delaying ovulation, and they do not induce abortion. On the other hand, the copper-bearing IUD prevents fertilization by causing a chemical alteration in both sperm and egg before they can meet. It is important to note that emergency contraception cannot terminate an established pregnancy or harm the development of an embryo. It is crucial to understand that any woman or girl of reproductive age may require emergency contraception to prevent an unwanted pregnancy. There are no absolute medical reasons to avoid using emergency contraception, and there are no age restrictions for its usage. The eligibility criteria for general use of a copper IUD also apply to its use for emergency purposes. According to the World Health Organization, emergency contraception (EC) can prevent over 95% of pregnancies when taken within 5 days after intercourse.
Emergency Contraceptive Pills (ECPS) Market- Market Dynamics
Increase in the number of unplanned pregnancies is expected to drive the growth of market
Unintended pregnancy is a significant global issue that imposes a considerable socioeconomic burden on individuals and society. Approximately 121 million pregnancies worldwide each year are unintended, accounting for nearly half of all pregnancies. For women and girls affected by this, the decision of whether or not to become pregnant is often not a choice at all. The State of World Population 2022 report, released by UNFPA, the United Nations sexual and reproductive health agency, highlights the urgent need for addressing this problem. To address the rise in unplanned pregnancies, there is a requirement for enhanced awareness and education about contraception. The market can experience growth through increased awareness about reproductive health and improved education on contraception methods, which can drive the demand for emergency contraceptive pills. However, it is important to consider that side effects and health concerns may hinder the growth of the market.
Emergency Contraceptive Pills (ECPS) Market- Key Insights
As per the analysis shared by our research analyst, the global Emergency Contraceptive Pills (ECPS) market is estimated to grow annually at a CAGR of around 2.5% over the forecast period (2023-2030)
Based on product type segmentation, Progesterone Pills was predicted to show maximum market share in the year 2022
Based on application segmentation, Drug Stores/ Pharmacy was the leading type in 2022
On the basis of region, North America was the leading revenue generator in 2022
The Global Emergency Contraceptive Pills (ECPS) Market is segmented on the basis of Product Type, Application and Region.
The market is divided into four categories based on product type: Combination Pills, Progesterone Pills, Estrogen Pills and Others. The market is primarily dominated by the Progesterone Pills segment. Although progesterone-only pills are commonly used as a regular contraceptive method, they are not typically employed as emergency contraception. Instead, Emergency Contraceptive Pills (ECPS), as previously mentioned, are specifically formulated for urgent situations that occur after unprotected intercourse.
The market is divided into four categories based on application: Drug Stores/ Pharmacy, Hospital Pharmacies, Online Traders and Other Channels. The market is largely dominated by the Drug Stores/Pharmacy segment. Over-the-counter Emergency Contraceptive Pills (ECPS) are readily available, and their presence in pharmacies is vital for addressing the immediate contraceptive requirements of individuals.
Emergency Contraceptive Pills (ECPS) Market- Geographical Insights
Geographically, this market is spread across various regions including North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. These regions are further divided based on the countries involved in business activities. The growth of the market is expected to be dominated by North America, primarily due to the increasing availability of emergency contraceptive products. North America boasts a well-established healthcare infrastructure, which facilitates the efficient distribution and accessibility of contraceptive products, including emergency contraceptive pills. 99% of sexually active women in the United States have used some form of contraception, with 87.5% opting for highly effective reversible methods as recommended by the American College of Obstetricians and Gynecologists. In the forecast period, Europe holds the second largest market share, mainly attributed to the growing awareness about contraception and family planning.
Various pharmaceutical companies worldwide manufacture and distribute emergency contraceptive pills, as they have obtained regulatory approval in numerous countries. The competitive landscape of this market can be influenced by advancements in reproductive health and alterations in regulations. To obtain the latest information on the competitive landscape of Emergency Contraceptive Pills, it is advisable to refer to official health agencies, pharmaceutical company websites, and recent market reports. Reputable online platforms offering ECPs may also contribute to competition by offering consumers convenient access to emergency contraception. For example, In Honduras, Optio developed Spanish versions of emergency contraception (EC) educational tools, to strengthen EC knowledge among health providers and community workers within Ashonplafa's network.
In November 2023, the trial for a new method of distributing emergency contraception pills (ECPs) without a prescription in Japan commenced, as reported by the Kyodo news agency. The Health, Labour and Welfare Ministry will be conducting this trial in 145 pharmacies, out of the over 60,000 pharmacies in the country. It is worth noting that Japan is among the few countries in the northern hemisphere where levonorgestrel (LNG) ECPs are still classified as prescription-only medications. To gain a deeper understanding of this research and trial, ECEC had the opportunity to interview Kazuko Fukuda, a prominent advocate for women's sexual and reproductive rights in Japan.